Search PubMed⌕ Search

Biomedical subjects

L Xerri

Publications and source records attributed to L Xerri.

At least 109 records · Page 6Linked to original sources
PubMed1989

Immunocytochemical assays in human endometrial carcinomas: a multiparametric computerized analysis and comparison with nonmalignant changes.

Immunocytochemical assay (ICAs) were performed on frozen sections from human endometrial samples (n = 89) including normal endometrium, decidua, hyperplasia with and without atypia, and carcinomas. Monoclonal antiestrogen receptor (ER), anti-laminin (Lam), anti-type IV collagen (Coll IV), and anti-Ki67 were applied with avidin-biotin-peroxidase complex or peroxidase-antiperoxidase complex. The results of the ICAs were evaluated through a computerized system of image analysis referred to as SAMBA. It was shown that this system provided for an accurate reliable and reproducible analysis of ICAs in tissue sections. It is concluded that this multiparametric and standardized method of analysis of ICAs can further be applied in correlations with clinical and biochemical data.

Antigens, Surface↗
PubMed1989

In-vitro activity of ofloxacin against Chlamydia trachomatis.

The in-vitro activity of ofloxacin was evaluated against recently isolated Chlamydia trachomatis strains from patients suffering from non-gonococcal urethritis. The minimal inhibitory concentration (MIC) proved to be 1 mg/l against 8 of the 10 strains assayed (the MICs for the other two strains were 0.5 and 2 mg/l). The data obtained confirm that ofloxacin is active against Chlamydia trachomatis at concentrations achievable with the routine dosage regimen. The drug may thus be regarded as potentially useful for the treatment of non-gonococcal urethritis due to Chlamydia.

Chlamydia trachomatis↗
PubMed1989

Type IV collagen immunostaining and computerized image analysis (SAMBA) in breast and endometrial disorders.

Type IV collagen immunostaining was performed on tissue sections from a large series of non-malignant and malignant disorders of the breast and endometrium. The results were analysed by means of a computerized system of image analysis referred to as SAMBA. It was shown that this system provided an accurate, reliable, reproducible, automated and multiparameteric analysis of collagen IV immunoprecipitates. It was concluded that this standardized method of analyses can be routinely used for the measurement of collagen IV, thus enabling correlations to be sought with histopathological and clinical data.

Basement Membrane↗
PubMed1989

[Giant leiomyoma of the inferior vena cava].

The authors report an uncommon case of giant leiomyoma of the inferior vena cava with intracardiac extension and arising from the external iliac vena. This case report illustrates the diagnostical problems usually encountered with this type of tumour. Indeed, despite ultrasound and transverse CT scan, the diagnosis was only assessed by histopathological analysis following a successful surgical removal of the leiomyoma. Only 7 cases of leiomyoma of the inferior vena cava are already reported in the literature. Relationship with intravenous leiomyomatosis of the uterus is also discussed.

Aged↗
PubMed1989

[Ultrastructural study of the liver in Niemann-Pick disease type C].

The authors report an electron microscopic study of the liver in a case of Niemann-Pick disease type C. The diagnosis was supported by clinical data, moderate increase of phospholipids, total cholesterol, leukocytes and liver sphingomyelin and sphingomyelinase activity. Intrasinusoidal liver foamy histiocytes were filled with lamellar and multivesicular inclusions similar to those observed in sphingomyelinase deficient patients. Hepatocytes contained a few non-specific lamellar inclusions occasionally associated with triglycerides and cholesterol crystals. These results are discussed with reference to the recent biochemical findings supporting the evidence of excessive accumulation of unesterified cholesterol in Niemann-Pick disease type C.

Humans↗
PubMed1989

[Association of sarcoidosis and primary biliary cirrhosis. Clinical and anatomopathologic study of a case followed for over 10 years].

A new case of primary biliary cirrhosis associated with sarcoidosis is reported in a 38 year-old woman. The diagnosis of sarcoidosis was based on the occurrence of cutaneous nodules, mediastinal lymph node enlargement, pulmonary reticular infiltrate, parotitis and diffuse arthritic pain, all disappearing after steroid therapy. Hepatic biopsy showed epithelioid-cell granuloma without necrosis. The diagnosis of primary biliary cirrhosis was made 6 years later as based on intrahepatic cholestasis associated with high titer of antimitochondrial antibodies and chronic destructive cholangitis. This association (5 other cases have already been reported) raises the problem of a possible link between the two diseases which could represent different patterns of a single immunological disorder.

Adult↗
PubMed1988

Importance of inoculum growth phase when using an in vitro pharmacokinetic model to evaluate beta-lactam antibiotics.

The bactericidal activity of cefuroxime, cephaloridine and cephalexin is evaluated in an in vitro model. The inocula are derived from an overnight static culture, or after a pre-incubation period of 1 or 2 hours to allow cell re-growth. The early bactericidal effect of the antibiotics is more evident using pre-incubated cells, especially for Staphylococcus aureus 663. At hour 8, with Escherichia coli 851/E, there is re-growth using the static inoculum, while the antibiotic effect is still evident using the pre-incubated one. The importance arises therefore for considering the phase of growth of the inoculum as a critical parameter when using in vitro models with varying concentrations of beta-lactam antibiotics.

Anti-Bacterial Agents↗
PubMed1987

Synergy of ceftazidime and human macrophages on phagocytosis and killing of Staphylococcus aureus and Pseudomonas aeruginosa.

The effect of ceftazidime on the phagocytic and bactericidal activity of human macrophages was investigated. At concentrations of half the MIC the antibiotic caused macrophages to ingest and kill Staphylococcus aureus and Pseudomonas aeruginosa at a higher level than did macrophages without drug. Bacteria pretreated with ceftazidime became more sensitive to the bactericidal activity of macrophage lysozyme. Macrophages taken from mice receiving intravenous ceftazidime showed greater phagocytic activity than those from control mice.

Ceftazidime↗
PubMed1987

Ofloxacin: in vitro and in vivo activity.

Ofloxacin is a new oral antibacterial fluoro-quinolone, endowed with potent bactericidal activity over a very broad bacterial spectrum. Ofloxacin's minimum bactericidal concentration (MBC) proved to be equal to the minimum inhibitory concentration (MIC) even at high inocula or in the presence of human serum with a high bactericidal rate. The effect of the presence of urine was that the bacteria were sensitive to higher drug concentrations, as in the case of other quinolones; these concentrations, however, are easily reached in the urinary tract after a single therapeutic dose in man. Ofloxacin proved to be extremely effective in curing experimental infections induced by both gram-positive and gram-negative pathogens.

Animals↗
PubMed1986

Ofloxacin: bactericidal effect in an in vitro pharmacokinetic model.

Ofloxacin has been evaluated in an in vitro model where microorganisms were exposed to the varying concentrations met in human serum after the oral administration of a 200 mg dose. The recently isolated strains were selected with minimum inhibitory concentrations (MICs) representative of the MICs 90% of ofloxacin against the species considered. Results showed that ofloxacin sterilized the bacterial cultures of S. aureus, P. morganii and E. coli, with 99.99% of killing still evident for P. aeruginosa after 12 hours of exposure. All the reference compounds (amoxicillin 1 g b.i.d., cefaclor 500 mg t.i.d., rifampicin 450 mg b.i.d.) showed, in the same test, worse results than ofloxacin.

Amoxicillin↗
PubMed1986

Ofloxacin: therapeutic activity in experimental infections.

The therapeutic activity of ofloxacin, a new oral fluoroquinolone antibacterial agent, was tested in experimental infections in rodents. Its activity was compared with that of nalidixic acid, norfloxacin, amoxicillin and cotrimoxazole in Pseudomonas aeruginosa pyelonephritis in the rat, and with that of amikacin and cefotaxime in Proteus morganii thigh infections in mice. Ofloxacin proved to be more effective than reference drugs, even if parenterally administered, in reducing the bacterial count in muscle, kidney and urine.

Administration, Oral↗
PubMed1985

Study on the antibacterial activity of ceftazidime in an in vitro pharmacokinetic model.

A kinetic model was used to evaluate the activity of ceftazidime against recently isolated bacterial strains. The microorganisms were subjected in vitro to drug concentrations simulating the serum kinetics of ceftazidime after i.v. administration of 1 g of the drug. In these conditions ceftazidime showed a bactericidal effect lasting up to 12 h, even at concentrations below the MICs for some strains. In no case did resistant populations develop after exposure to the drug.

Bacteria↗
PubMed1984

In vitro evaluation of ceftazidime (GR 20263), amikacin and sisomicin, in a model simulating serum pharmacokinetics of therapeutic doses.

The activity of ceftazidime, amikacin and sisomicin was investigated in an in vitro model using varying concentrations of antibiotic which mimic the serum levels of patients after the intramuscular administration of a 500, 250 and 70 mg dose respectively. Using this test, during the time of the agar MIC value correlation, ceftazidime, amikacin and sisomicin proved to be active against strains sensitive to 16 micrograms/ml, 8 micrograms/ml and 4 micrograms/ml respectively. Using the above concentrations as the cut-off points in defining the sensitivity of the strains, ceftazidime revealed the same level of activity as amikacin (6 and 5 resistant strains respectively out of the 185 tested) and proved much more active than sisomicin (48 resistant strains).

Amikacin↗
PubMed1983

Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.

The pharmacokinetics and clinical efficacy of ceftazidime, a cephalosporin with activity against Pseudomonas aeruginosa, were studied in children with cystic fibrosis. Ceftazidime had high in vitro activity against P. aeruginosa strains isolated from our patients, with a mean MIC90 of 8 micrograms/ml. The first dose of 50 mg/kg IV of ceftazidime achieved serum concentrations of 40.8 +/- 19.7 micrograms/ml at one hour and 3.8 +/- 1 micrograms/ml at four hours after administration (mean values +/- SD). The MIC90 was exceeded by serum concentrations for up to three hours. The elimination of the drug from the blood followed a biexponential decay with an elimination half-life of 60.4 +/- 6.8 min and a total body clearance of 6.0 +/- 3.1 ml/min/kg. Renal clearance of the drug accounted for 75% of the total clearance; these are higher values than those reported for adults. Peak concentrations of ceftazidime in the sputum two hours after a single administration were 4.13 +/- 2.06 micrograms/ml; after seven and 14 days of treatment, sputum concentrations were significantly lower. Eleven children with acute pulmonary exacerbation were treated for 14 days with ceftazidime at a dose of 150 mg/kg/day (12 treatment courses). Significant clinical and radiologic improvements were obtained in nine of 12 patients. In six of 11 cases the P. aeruginosa count decreased by 10(4) CFU/ml. Ceftazidime was well tolerated, and no side effects appeared during treatment.

Acute Disease↗